NautaDutilh assisted NewAmsterdam Pharma with an upsized underwritten public offering of ordinary shares and pre-funded warrants on Nasdaq.
The ordinary shares were offered at an offer price of USD 24,50 per share and the pre-funded warrants at an offer price of USD 24,4999 per pre-funded warrant. The net proceeds to NewAmsterdam Pharma are expected to be approximately USD 452.6 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the company.
“It has been an absolute pleasure working alongside Covington & Burling LLP in this transaction, together assisting NewAmsterdam with yet another offering following their successful offering in February 2024, as NewAmsterdam Pharma continues their journey to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well-tolerated.”
Next to Paul and Nina Kielman (lead tax partner) the team consisted of Marloes van der Laan, Eline van Marle, Joppe Schoute and Daan Hagelstein.